Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

Derived from scRNA-seq, SLC26A3 is a potential therapeutic target to improve the efficacy of immunotherapy, as well as a potential diagnostic indicator to reduce post-surgical upstaging, for cervical ...

Recent advances in ADC design have led to a rapid increase ... drug resistance and tumor heterogeneity. Historically, ADCs with dual payloads have been very difficult to manufacture, but ...

Most tumors are comprised of heterogeneous cancer cells with distinct gene-expression profiles and differing sensitivity to various drugs. Even with effective single-agent ADC treatments ...

We will specifically focus on how these integrated approaches are advancing our understanding of tumor heterogeneity with implications for patient response to ADCs and immunotherapies. Join us to ...

Beyond novel ADC designs, it is notable that novel ADC ... This dual specificity is especially useful for heterogeneous tumors or conditions where pathogenic cells express different markers.

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

SOT112 is a bispecific ADC with potential applicability in several ... precision and the potential to overcome the challenges of heterogeneity in solid tumor target expression.

Three-program alliance with Synaffix reflects SOTIO's commitment to further broaden and advance innovative ADC pipeline SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF ...